Aurinia Pharmaceuticals Inc (AUPH) Financial Statements (2024 and earlier)

Company Profile

Business Address #140, 14315 - 118 AVENUE
EDMONTON, AB T5L 4S6
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments337,060350,395360,860389,306375,933391,512
Cash and cash equivalents45,55781,38988,32794,08885,341151,408
Short-term investments291,503269,006272,533295,218290,592240,104
Inventory, net of allowances, customer advances and progress billings32,82033,15531,74524,75225,32025,863
Inventory32,82033,15531,74524,75225,32025,863
Prepaid expense16,15811,33210,09613,58012,15917,421
Deposits current assets      4,109
Other current assets1,6451,2081,2271,3343,8081,088
Other undisclosed current assets38,78619,81719,72013,56742,48213,200
Total current assets:426,469415,907423,648442,539459,702453,193
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization113,069117,428    
Operating lease, right-of-use asset4,6094,7144,8134,9074,9455,079
Property, plant and equipment3,4963,6503,8423,6503,7584,183
Long-term investments and receivables591     
Long-term investments591     
Intangible assets, net (including goodwill)5,2615,6836,1016,4256,8397,338
Intangible assets, net (excluding goodwill)5,2615,6836,1016,4256,8397,338
Other noncurrent assets1,5181,51813,35713,33913,04912,355
Total noncurrent assets:128,544132,99328,11328,32128,59128,955
TOTAL ASSETS:555,013548,900451,761470,860488,293482,148
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:52,30941,37535,96539,99040,12332,380
Accounts payable8,8544,8083,6803,087  
Accrued liabilities24,34017,42515,97522,9335,4114,499
Other undisclosed accounts payable and accrued liabilities19,11519,14216,31013,97034,71227,881
Deferred revenue4,6623,2283,1573,148  
Debt13,32814,016    
Other liabilities2,6112,0881,9792,0337241,293
Other undisclosed current liabilities980954945936918953
Total current liabilities:73,89061,66142,04646,10741,76534,626
Noncurrent Liabilities
Long-term debt and lease obligation72,19379,422  7,2707,431
Finance lease, liability72,19379,422    
Liabilities, other than long-term debt17,05315,52519,30719,31815,83316,323
Other liabilities10,3408,71112,32112,16615,83316,323
Operating lease, liability6,7136,8146,9867,1527,2707,431
Total noncurrent liabilities:89,24694,94719,30719,31823,10323,754
Total liabilities:163,136156,60861,35365,42564,86858,380
Equity
Equity, attributable to parent, including:391,877392,292390,408405,435423,425423,768
Additional paid in capital109,71198,83288,88585,48979,18874,004
Accumulated other comprehensive loss(947)(1,020)(988)(1,061)(1,527)(1,853)
Accumulated deficit(915,447)(902,000)(890,508)(864,302)(838,256)(829,267)
Other undisclosed equity, attributable to parent1,198,5601,196,4801,193,0191,185,3091,184,0201,180,884
Total equity:391,877392,292390,408405,435423,425423,768
TOTAL LIABILITIES AND EQUITY:555,013548,900451,761470,860488,293482,148

Income Statement (P&L) ($ in thousands)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
Revenues54,51541,49434,40928,43555,77928,191
Cost of revenue(6,769)(1,563)(421)(1,362)(2,447)(1,599)
Cost of goods and services sold    (1,182)  
Gross profit:47,74639,93133,98827,07353,33226,592
Operating expenses(61,364)(59,731)(63,282)139,028(63,142)(63,057)
Other operating income (expense), net(2,645)3,630(290)2,170311476
Other undisclosed operating loss   (196,371)  
Operating loss:(16,263)(16,170)(29,584)(28,100)(9,499)(35,989)
Interest and debt expense(1,400)(65)    
Loss from continuing operations before equity method investments, income taxes:(17,663)(16,235)(29,584)(28,100)(9,499)(35,989)
Other undisclosed income from continuing operations before income taxes4,5144,1013,8142,9091,464483
Loss from continuing operations before income taxes:(13,149)(12,134)(25,770)(25,191)(8,035)(35,506)
Income tax expense (benefit)(298)642(436)(855)(954)(9)
Loss from continuing operations:(13,447)(11,492)(26,206)(26,046)(8,989)(35,515)
Loss before gain (loss) on sale of properties:(8,989)(35,515)
Net loss available to common stockholders, diluted:(13,447)(11,492)(26,206)(26,046)(8,989)(35,515)

Comprehensive Income ($ in thousands)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
Net loss:(13,447)(11,492)(26,206)(26,046)(8,989)(35,515)
Other comprehensive income (loss)    466326(235)
Comprehensive loss:(13,447)(11,492)(26,206)(25,580)(8,663)(35,750)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent73(32)73   
Comprehensive loss, net of tax, attributable to parent:(13,374)(11,524)(26,133)(25,580)(8,663)(35,750)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: